Replies to post #227960 on Biotech Values

[DewDiligence]

DRRX—(-75%)—misses primary endpoint in alcoholic hepatitis:

https://finance.yahoo.com/news/durect-corporation-announces-topline-results-210100751.html

The numerical improvement in the primary endpoint of mortality or transplant at 90 days did not achieve statistical significance for either dose of larsucosterol.

DRRX has a long history of clinical failures.